Listen
Reason for request
Inclusion for hospital use in the extension of indication for maintenance treatment of follicular lymphoma in previously untreated patients.
-
Clinical Benefit
| Substantial |
The actual benefit of MabThera in the maintenance treatment of previously untreated non-Hodgkin's follicular lymphoma is substantial. |
Clinical Added Value
| important |
MabThera as maintenance treatment for previously untreated follicular lymphoma, provides an important improvement in actual benefit (IAB II) in terms of efficacy in the management of patients who respond to first-line induction therapy. |
English version
Contact Us
Évaluation des médicaments
